Recursion Pharmaceuticals RXRX
Recursion Pharmaceuticals reported a $119.04 million net loss
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001601830-26-000145
- Revenue of $18.55 million for the three months ended Sep 30, 2026
- Diluted EPS of -$0.22 for the three months ended Sep 30, 2026
- Cash and equivalents of $549.85 million at Sep 30, 2026
Written from the 10-Q on EDGAR. Check the filing before you rely on it.
What changed since last quarter
No new risk factors or legal mentions.
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Revenue | $18.55M | $7.67M | +142% |
| Operating income and margin | −$123.18M · -663.9% | −$134.97M · -1759.7% | +8.7%, margin +1095.8 pts |
| Net income | −$119.04M | −$131.01M | +9.1% |
| Operating cash flow | −$77.41M | −$105.95M | +27% |
| Cash | $549.85M | $545.68M | +0.8% |
The reading, claim by claim
0 of 5 claims matched the filing text.
Not found in the filing text
- For the quarter ended June 30, 2026, RECURSION PHARMACEUTICALS, INC. reported revenue of $7.7 million.
- The company recorded a net loss of $131.0 million.
- Gross margin was -49.8%, and operating margin was -1759.7%.
- Net margin for the quarter was -1708.0%.
- Revenue decreased by 60.1% compared to the same period a year earlier.
Similar companies
Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.
- Bausch Health Companies BHC public float $2.0B, Jun 30, 2025
- Vericel VCEL public float $2.1B, Jun 30, 2025
- Agios Pharmaceuticals AGIO public float $1.9B, Jun 30, 2025
- Biocryst Pharmaceuticals BCRX public float $1.9B, Jun 30, 2025
- Indivior Pharmaceuticals INDV public float $1.8B, Jun 30, 2025